{"id":"W4399786010","doi":"10.1093/neuonc/noae064.431","title":"LGG-40. TYPE II RAF INHIBITOR TOVORAFENIB IN RELAPSED/REFRACTORY PEDIATRIC LOW-GRADE GLIOMA (PLGG): REVERSIBLE DECREASES IN GROWTH VELOCITY IN THE PHASE 2 FIREFLY-1 TRIAL","year":2024,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Montreal Children's Hospital; McGill University Health Centre; Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine; Université Laval","funders":"University of California, San Francisco; Medical School, University of Michigan; Université de Montréal; Rigshospitalet; Humboldt-Universität zu Berlin; Centre Hospitalier Universitaire de Québec; Great Ormond Street Institute of Child Health; Great Ormond Street Hospital for Children; Tel Aviv University; Seoul National University; College of Medicine, Seoul National University; Gentofte Hospital; Yonsei University; Newcastle University; Cancer Research Institute; Texas Children's Hospital; McGill University; McGill University Health Centre; Deutsches Krebsforschungszentrum; Freie Universität Berlin; Université Laval","keywords":"Refractory (planetary science); Glioma; Internal medicine; Medicine; Firefly protocol; Gastroenterology; Oncology; Cancer research; Biology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007144066,0.0003410388,0.0007209664,0.001025374,0.00008641694,0.00003349342,0.0002348132,0.0003845246,0.0001717509],"category_scores_gemma":[0.001289398,0.0002551767,0.0001826575,0.002314222,0.00009668014,0.0001376143,0.0001276547,0.0008936925,0.00008955628],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007477719,"about_ca_system_score_gemma":0.0009061237,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004333309,"about_ca_topic_score_gemma":0.0005778534,"domain_scores_codex":[0.9969598,0.0006349845,0.0007438843,0.0007000632,0.000387846,0.0005734112],"domain_scores_gemma":[0.9972872,0.001943626,0.0001294155,0.0003966914,0.00005993589,0.0001831115],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"case_report","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.1450414,0.1042366,0.1207127,0.001495946,0.0003547135,0.197626,0.0119971,0.00006365916,0.1797441,0.001430548,0.1899605,0.04733661],"study_design_scores_gemma":[0.6053315,0.06066563,0.05905776,0.0008982076,0.001573881,0.001701749,0.001352285,0.001067334,0.04767327,0.001442887,0.2175797,0.001655726],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9871821,0.002915357,3.655073e-7,0.005509623,0.001835737,0.001605196,0.00002027741,0.00008193701,0.0008493479],"genre_scores_gemma":[0.9965749,0.0009115566,0.00005685499,0.00106193,0.0009864565,0.0002904588,0.00005508732,0.00004562856,0.00001708124],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4602901,"threshold_uncertainty_score":0.99999,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02920981703444509,"score_gpt":0.3246425832411657,"score_spread":0.2954327662067206,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}